摘要
目的探讨炎症因子高敏C反应蛋白(hs-CRP)在使用双胍类和磺脲类联合治疗12周后的2型糖尿病患者中的变化。方法采用免疫比浊法定量检测48例2型糖尿病患者治疗前后hs-CRP的水平,酶法检测空腹血糖(FBG)、血脂,高效液相法检测糖化血红蛋白(HbA1c),比较其治疗前后的变化。结果2型糖尿病患者治疗前后体质量指数(25.62±2.92)vs(25.09±2.98),腰围(85.73±8.66)cm vs(84.75±8.72)cm,FBG(7.92±1.43)mmol/L vs(5.96±1.31)mmol/L,总胆固醇(5.63±1.08)mmol/L vs(4.98±0.79)mmol/L,甘油三酯(2.19±2.09)mmol/L vs(1.58±0.96)mmol/L,低密度脂蛋白胆固醇(3.29±1.17)mmol/L vs(2.91±0.59)mmol/L,hs-CRP(1.66±0.93)mg/L vs(1.20±0.86)mg/L,HbA1c(7.29±1.26)%vs(6.79±0.96)%;上述指标治疗后较治疗前明显下降,其差异有统计学意义(均P<0.01)。结论2型糖尿病患者在血糖、体质量和腰围控制的同时hs-CRP水平降低,hs-CRP可作为临床医生治疗2型糖尿病及其血管并发症时疗效观察的监测指标之一。
Objective To study the effect of metformln and sulfonylurea on high sensitive C-reactive protein (hs-CRP) level in type 2 diabetic patients. Methods Hs-CRP level was determined by immuoturbidimetric method in 48 cases of type 2 diabetes treated with metformin and sulfonylurea. Also,their fasting blood glucose(FBG), blood cholesterol,glycosylated hemoglobin(1c)(HbA1c) were detected. Results Type 2 diabetes patients showed significant differences before and after treatment in body mass index(25.62±2.92) vs (25.09 ±2.98), waist circumference (85.73±8.66) cm vs (84.75±8.72) cm, FBG(7.92 ±1.43) mmol/L vs (5.96 ±1.31) mmol/L, total cholesterol (5.63±1.08) mmol/L vs (4.98±0.79) mmol/L, triglycerides (2.19±2.09) mmol/L vs (1.58±0.96) mmol/L, low-density lipoprotein cholesterol(3.29±1.17) mmol/L vs (2.91 ±0.59) mmol/L, hs-CRP(1. 66±0. 93) mg/L vs (1.20±0.86) mg/L,HbA1c(7.29±l. 26);vs (6.79±0.96)%,(all P〈0.01). Conclusion Hs-CRPlevelreduces in type 2 diabetic patients while their blood glucose, body mass index and waist circumference are controlled. Hs-CRP can be an effective factor in the evaluation of treatments for type 2 diabetes.
出处
《临床荟萃》
CAS
北大核心
2007年第19期1386-1388,共3页
Clinical Focus